Aadi Bioscience recalls Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound), 100 mg per vial, NDC 80803-153-50,
Recalled November 23, 2022 · FDA recall D-0059-2023 · Aadi Bioscience
Hazard
Failed Stability Specifications · FDA Class III
Units
2,333 vials
Sold at
Within the U.S Market - PA, AL, KY, TN
Description
Failed Stability Specifications
Product
Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound), 100 mg per vial, NDC 80803-153-50, manufactured for Aadi Bioscience, Inc, CA.
Manufacturer(s)
Aadi Bioscience
Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →